Market Research Logo

Global Bipolar Disorder Therapeutic Market 2017-2021

Global Bipolar Disorder Therapeutic Market 2017-2021

About Bipolar Disorder Therapeutic

Bipolar disorder, also called manic-depressive disorder, is a mental disorder that causes unusual mood swings in patients. The disease causes periods of depression and mania in patients.

Technavio’s analysts forecast the global bipolar disorder therapeutic market to grow at a CAGR of 2.22% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global bipolar disorder therapeutic market for 2017-2021. To calculate the market size, the report considers the sales of drugs in the bipolar disorder therapeutic market.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Bipolar Disorder Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Eli Lilly
  • Bristol-Myers Squibb
  • AstraZeneca
Other prominent vendors
  • Allergan
  • Astellas Pharma
  • GlaxoSmithKline
  • Janssen Pharmaceuticals
Market driver
  • Need to reduce financial burden of bipolar disorder
  • For a full, detailed list, view our report
Market challenge
  • Lack of adequate diagnostic process
  • For a full, detailed list, view our report
Market trend
  • Awareness about bipolar disorder in children (pediatric extension)
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Bipolar Disorder Therapeutic Market 2017-2021

Technavio recognizes the following companies as the key players in the global bipolar disorder therapeutic market: Eli Lilly, Bristol-Myers Squibb, and AstraZeneca.

Other Prominent Vendors in the market are: Allergan, Astellas Pharma, GlaxoSmithKline, and Janssen Pharmaceuticals.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is awareness about bipolar disorder in children (pediatric extension). Although most children experience mood swings as a part of growing up, these mood swings may often persist for a longer period and interfere with the daily life of the child. Bipolar disorder is one of the causes of these mood swings. Although the disease is rarely diagnosed in children, awareness about the disease among children has been rising.”

According to the report, one of the major drivers for this market is need to reduce financial burden of bipolar disorder. Mental health disorder has an estimated cost of $100 billion in the US. Similarly, one out of four people in Europe has a mental disorder. The severe effect of mental disorders can be understood from the fact that six out of 20 countries with the highest rates of suicide belong to Europe. To address this scenario, governments and companies are organizing awareness camps to raise disease awareness among the public.

Further, the report states that one of the major factors hindering the growth of this market is lack of adequate diagnostic process. The lack of a proper technical diagnostic process and high dependency on psychiatric diagnosis increases uncertainty in the results obtained. The diagnosis relies significantly on factors such as family history and collaborative information of personal and professional life. Also, doctors are often unable to distinguish bipolar disorder from other mental disorders. Studies indicate an average delay of six years in the diagnosis of people with bipolar disorder.

Companies Mentioned

Eli Lilly, Bristol-Myers Squibb, AstraZeneca, Allergan, Astellas Pharma, GlaxoSmithKline, and Janssen Pharmaceuticals.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Key market highlights
  • Disease overview
    • Table Different types of bipolar disorder
    • Table Factors causing bipolar disorder
    • Table Medication guidelines for managing bipolar disorder
  • Market landscape
    • Market overview
      • Table Global bipolar disorder therapeutics market: Snapshot
    • Market size and forecast
      • Table Global bipolar disorder therapeutic market 2016-2021($ millions)
      • Table Global bipolar disorder therapeutic market: Opportunity analysis
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline landscape
    • Table Pipeline snapshot
    • Table Pipeline landscape
  • Market segmentation by drug class
    • Market overview
      • Table Global bipolar disorder therapeutic market by drug class 2016 and 2021
      • Table Global bipolar disorder therapeutic market by drug class
    • Antipsychotics
      • Table Uses and side-effects of antipsychotics
      • Table Global bipolar disorder antipsychotics drugs market 2016-2022 ($ millions)
    • Anticonvulsants
      • Table Old generation anticonvulsants for bipolar disorder treatment: Snapshot
      • Table New generation anticonvulsants for bipolar disorder treatment: Snapshot
      • Table Uses and side-effects of anticonvulsants
      • Table Global bipolar disorder antipsychotic drug market 2016-2022 ($ millions)
    • Traditional mood stabilizers
      • Table Global bipolar disorder traditional mood stabilizers drug market 2016-2022 ($ millions)
    • Others
      • Table Global bipolar disorder therapeutic market for other drugs 2016-2022 ($ millions)
  • Geographical segmentation
    • Table Global bipolar disorder therapeutic market by geography 2016 and 2021
    • Table Bipolar disorder therapeutic market by geography 2016-2021 ($ millions)
    • Bipolar disorder therapeutics market in Americas
      • Table Market scenario in Americas
      • Table Bipolar disorder therapeutic market in Americas 2016-2021 ($ millions)
    • Bipolar disorder therapeutic market in EMEA
      • Table Market scenario in EMEA
      • Table Bipolar disorder therapeutic market in EMEA 2016-2021 ($ millions)
    • Bipolar disorder therapeutic market in APAC
      • Table Market scenario in APAC
      • Table Bipolar disorder treatment market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Economic burden of mental illnesses
      • Table Initiatives for people with mental disorders
    • Impact of drivers on key customer segments
      • Table Impact of drivers
    • Market challenges
      • Table Financial loss due to patent issues
      • Table Major side-effects of bipolar disorder medications
    • Impact of challenges on key customer segments
      • Table Impact of challenges
  • Market trends
    • Awareness about bipolar disorder in children (pediatric extension)
    • Rising application of combination therapies
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global bipolar disorder therapeutic market 2016
      • Table Strategic success factors of companies in global bipolar disorder therapeutic market
  • Key vendor analysis
    • Eli Lilly
      • Table Eli Lilly: Key highlights
      • Table Eli Lilly: Strength assessment
      • Table Eli Lilly: Strategy assessment
      • Table Eli Lilly: Opportunity assessment
      • Table Eli Lilly: YoY growth rate of Zyprexa 2014-2015 ($ millions)
    • Bristol-Myers Squibb
      • Table Bristol-Myers Squibb: Key highlights
      • Table Bristol-Myers Squibb: Strength assessment
      • Table Bristol-Myers Squibb: Strategy assessment
      • Table Bristol-Myers Squibb: Opportunity assessment
      • Table Bristol-Myers Squibb: Revenue and YoY growth rate of Abilify 2013-2015 ($ millions)
    • AstraZeneca
      • Table AstraZeneca: Key highlights
      • Table AstraZeneca: Strength assessment
      • Table AstraZeneca: Strategy assessment
      • Table AstraZeneca: Opportunity assessment
      • Table AstraZeneca: Revenue and YoY growth rate of Seroquel 2013-2015 ($ millions)
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report